Feb 17, 2022 / 03:00PM GMT
Yigal Dov Nochomovitz - Citigroup Inc., Research Division - Director
Welcome, everyone, to day 2 of Citi's Immuno-Oncology Summit. I am Yigal Nochomovitz, one of the biotech analysts here at Citi. Most of you know me. (Operator Instructions)
So with that, it's my great pleasure to welcome the management team from Adaptimmune. We have Gavin Wood, CFO; Elliot Norry, CMO; and Juli Miller, VP IR. So welcome, everyone. Thank you so much for taking the time. Maybe just to start out, Gavin, if you would like to summarize the overall strategy for Adaptimmune for those listeners that are less familiar with the story?
Adrian G. Rawcliffe - Adaptimmune Therapeutics plc - CEO, Principal Accounting Officer & Director
It's Ad Rawcliffe, CEO. I'll just touch on areas of focus for this year. Adaptimmune is a late-stage, integrated cell therapy company, focused on the TCR T-cell space for solid tumors. We have a strategy that we laid out a couple of years ago. It's unashamedly a product-oriented strategy as we're leading in late-stage clinical trials and approaching
Adaptimmune Therapeutics PLC at Citi Immuno-Oncology Summit (Virtual) Transcript
Feb 17, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers